Sandoz US News
Princeton, New Jersey, July 21, 2016– Sandoz today announced the U.S. market introduction of rosuvastatin calcium tablets, a generic version of Crestor® by AstraZeneca Pharmaceuticals LP 1.
Holzkirchen, 13 July, 2016. Sandoz, a Novartis division and leader in biosimilars, announced today that the US Food and Drug Administration (FDA) Arthritis Advisory Committee recommended approval of its proposed biosimilar etanercept. The committee voted unanimously (20-0), in support of biosimilar etanercept for all five indications of the reference product, including rheumatoid arthritis (RA), plaque psoriasis (PsO), psoriatic psoriasis (PsA), ankylosing spondylitis (AS) and polyarticular juvenile idiopathic arthritis (JIA).
Holzkirchen, July 7, 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met. The study compared the efficacy and safety of its biosimilar etanercept candidate with the originator product, Enbrel®*** in patients with moderate to severe chronic plaque-type psoriasis and was presented at Psoriasis 2016, the 5th Congress of the Psoriasis International Network (PIN), Paris, France.
Visit our multimedia gallery to learn about Sandoz.
Click below for important links.
Our people are our greatest resource. We are always looking for new colleagues to share in our passion and commitment to making the world a healthier place.
Transitioning to civilian service soon? Consider a career with Sandoz, a Novartis company. Learn about our mission, and why you should explore being a part of our team.
Sandoz is a world leader in generic pharmaceuticals, providing access to a wide array of high-quality, affordable medicines. In the US, Sandoz markets more than 200 different generic drugs, including enoxaparin sodium injection, the first generic version of Lovenox®, and Omnitrope®, the groundbreaking follow-on biologic. Our 2,300 US associates are proud to make Sandoz a "healthy decision."
As part of the Novartis group, we believe that superior quality is the key to our long-term success. Our state-of-the-art technologies, decades of experience, and rigorous across-the-board quality standards all contribute to our broad portfolio of premium quality generic medicines.
We use innovation and expertise to go beyond standard generics and develop even the most complex medicines, which add value to patient healthcare – from generic injectables and ophthalmics to biosimilars and respiratory. Driving patient access to cost-effective treatment is how we are shaping the future of healthcare.
Sandoz was the first company to develop and market follow-on versions of highly-complex biopharmaceuticals. Today, we are the undisputed global leader in this segment and have an industry-leading pipeline that will make essential biologics more affordable for all.